Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 28;13(1):144.
doi: 10.1186/s13045-020-00978-z.

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Eric Powers  1 , Georgia Sofia Karachaliou  2   3 , Chester Kao  1 , Michael R Harrison  2   3 , Christopher J Hoimes  2   3 , Daniel J George  2   3 , Andrew J Armstrong  2   3   4 , Tian Zhang  5   6
Affiliations
Review

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Eric Powers et al. J Hematol Oncol. .

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.

Keywords: Androgen receptor inhibitors (ARIs); Castration-resistant prostate cancer; Metastatic prostate cancer; Polyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor; Prostate-specific membrane antigen (PSMA).

PubMed Disclaimer

Conflict of interest statement

TZ: research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, and Astellas; consulting/speaking with Genentech Roche, Exelixis, Genomic Health, and Sanofi Aventis; and consulting with AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, BMS, MJH Associates, and IQVIA. Stock ownership/employment/consulting (spouse) from Capio Biosciences, Archimmune Therapeutics, & Nanorobotics. CJH: Research funding from Merck, consulting from Merck, BMS, Seattle Genetics, Eisai, Bayer, Genentech; Speakers bureau for BMS, Eisai, Genentech. AJA: Consulting with Pfizer, Astellas, Janssen, Bayer, Astrazeneca, and Merck and research funding (to Duke) from Pfizer, Astellas, Janssen, Bayer, Dendreon, Novartis, Genentech/Roche, Merck, BMS, Astrazeneca, Constellation, and Beigene, DJG: Research from Acerta Pharmaceuticals, Astellas, Bayer, BMS, Calithera, Exelixis, Janssen Pharmaceuticals, Novartis, Pfizer, Sanofi Aventis; Consultant or Advisory board for Astellas, AstraZeneca, Axess Oncology, Bayer H/C Pharmaceuticals, BMS, Capio Biosciences, Exelixis, Flatiron, Janssen, Merck, MJH Associates, Modra Pharmaceuticals, Myovant Sciences, Physician Education Resource LLC, Pfizer, Sanofi Aventis, and Vizuri Health Sciences LLC; Honoraria or travel fees from Bayer, EMD Serono, Exelixis, Ipsen, MJH Associates, Pfizer, Sanofi Aventis, UroGPO, and UroToday. MRH: Acerta; research funding, Astellas; research funding, AstraZeneca; research funding, consulting, Bayer; research funding, consulting, Bristol Myers Squibb; research funding, consulting, Clovis Oncology; research funding, Exelixis; research funding, consulting, promotional speaking, FujiFilm; consulting, Genentech; consulting, promotional speaking, Janssen; consulting, Merck; research funding, Pfizer; research funding, consulting, Seattle Genetics; research funding EP, GSK, CK: None.

Figures

Fig. 1
Fig. 1
Summary of novel therapeutic categories in metastatic castration-resistant prostate cancer
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin (Internet) 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med (Internet) 2015;373:737–746. doi: 10.1056/NEJMoa1503747. - DOI - PMC - PubMed
    1. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (Internet) 2016;387:1163–1177. doi: 10.1016/S0140-6736(15)01037-5. - DOI - PMC - PubMed
    1. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol (Internet) 2019;37:2974–2986. doi: 10.1200/JCO.19.00799. - DOI - PMC - PubMed
    1. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med (Internet) 2019;381:121–131. doi: 10.1056/NEJMoa1903835. - DOI - PubMed

MeSH terms

LinkOut - more resources